Compare KRYS & GATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRYS | GATX |
|---|---|---|
| Founded | 2015 | 1898 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 6.6B |
| IPO Year | 2017 | 1994 |
| Metric | KRYS | GATX |
|---|---|---|
| Price | $298.90 | $171.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 2 |
| Target Price | ★ $297.60 | $215.50 |
| AVG Volume (30 Days) | ★ 273.5K | 174.6K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.36% |
| EPS Growth | ★ 128.00 | 17.22 |
| EPS | 1.83 | ★ 2.35 |
| Revenue | $389,130,000.00 | ★ $1,740,400,000.00 |
| Revenue This Year | $38.74 | $42.21 |
| Revenue Next Year | $32.53 | $3.35 |
| P/E Ratio | $166.58 | ★ $73.52 |
| Revenue Growth | ★ 33.94 | 9.77 |
| 52 Week Low | $123.03 | $144.56 |
| 52 Week High | $319.48 | $205.56 |
| Indicator | KRYS | GATX |
|---|---|---|
| Relative Strength Index (RSI) | 55.98 | 33.30 |
| Support Level | $253.89 | $166.88 |
| Resistance Level | $319.48 | $175.83 |
| Average True Range (ATR) | 11.79 | 4.85 |
| MACD | -0.87 | -2.15 |
| Stochastic Oscillator | 46.86 | 9.51 |
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
GATX Corp leases transportation assets, including railcars, aircraft spare engines, and tank containers, to customers in North America, Europe, and India. The company's reportable business segments are: Rail North America, Rail International, Engine Leasing, and Other. The majority of its revenue is generated from the Rail North America segment, which is composed of the company's operations in the United States, Canada, and Mexico. This segment mainly provides railcars pursuant to full-service leases under which it maintains the railcars, pays ad valorem taxes and insurance, and provides other ancillary services.